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Schizophrenia and related psychotic disorders are among the most
disabling illnesses worldwide1 and pose a considerable economic
burden to current healthcare systems.2,3 Information on the
cost-effectiveness of alternative treatment approaches for
psychosis is therefore highly relevant for decision makers in the
field of healthcare. Cognitive–behavioural therapy (CBT) can help
to psychologically overcome persistent symptoms and improve the
degree of normal functioning in everyday life.4–10 Surprisingly,
until now only a few studies have focused on economic aspects
of CBT in psychosis. Several studies have found that CBT was
not more expensive than care as usual and sometimes found lower
societal costs.11–15 Although these results suggest that CBTmay be
a cost-effective intervention for psychosis, the evidence is limited.
The current study aims to determine the balance between costs
and health outcomes for CBT compared with treatment as usual
(TAU) in people with schizophrenia-spectrum disorder with
persistent and recurrent symptoms of psychosis.
Method
Study design and randomisation procedure
The study was designed as a multisite randomised controlled trial
(ISRCTN57292778) with a CBTand a TAU condition. The Central
Committee for Research involving Human Subjects approved the
study. When the inclusion criteria were met, written informed
consent was requested. The randomisation was stratified over six
regions in The Netherlands and performed independently by
University Medical Center Groningen.
Study population
The study population comprised people with schizophrenia or
schizoaffective disorder with persistent symptoms despite
adequate antipsychotic medication. Two university hospitals and
seven mental health centres in The Netherlands participated in
the study.
The inclusion criteria were:
(a) age 18–64;
(b) diagnosis of schizophrenia or schizoaffective disorder
(DSM–IV–TR, 295.xx)16
(c) Positive and Negative Syndrome Scale (PANSS)17 scores of
delusions 54 OR hallucinations 54 OR suspiciousness
54) AND Psychotic Symptoms Rating Scale (PSYRATS)18
scores delusions-suffering 52 AND delusions-impact 52
OR hallucinations-suffering 52 AND hallucinations-impact
52;
(d) treatment resistance defined as failure of two or more anti-
psychotic treatments of at least 6 weeks over the past
2 years.
The exclusion criteria were: intellectual disabilities with
IQ580; severe addiction; no competence in the Dutch language;
and previous exposure to CBT.
59
Cognitive–behavioural therapy for persistent
and recurrent psychosis in people
with schizophrenia-spectrum disorder:
cost-effectiveness analysis
Mark van der Gaag, A. Dennis Stant, Kerstin J. K. Wolters, Erik Buskens and Durk Wiersma
Background
Evidence on cost-effectiveness is important to make well-
informed decisions regarding care delivery.
Aims
To determine the balance between costs and health
outcomes of cognitive–behavioural therapy (CBT) compared
with treatment as usual (TAU) in people with schizophrenia
who have persistent and recurrent symptoms of psychosis.
Trial number: ISRCTN57292778.
Method
A total of 216 people were randomised and followed up for
18 months. The primary clinical outcome measure was time
functioning within the normal range. Normal functioning was
defined as social functioning within the 95% range of the
general population and no or minimal suffering and/or no or
minimal affect on daily life of persistent psychotic symptoms.
The difference in number of days was estimated. Using a
societal perspective, cost differences were estimated and
combined with clinical outcome to yield an incremental cost-
effectiveness ratio (ICER). Uncertainty was accessed using
bootstrapping and displayed by means of a cost-
effectiveness acceptability curve.
Results
In the CBT group, participants experienced 183 days of
normal social functioning, whereas the TAU group
experienced 106 days. The ICER was e47 per day of normal
functioning gained. Cognitive–behavioural therapy implies
higher costs, yet results in better health outcomes. Sensitivity
analyses showed that targeting individuals who have not
been hospitalised before receiving CBT results in an ICER of
e14 per day normal functioning gained.
Conclusions
Days of normal functioning improved in the CBT condition
compared with TAU, but this gain in health was associated
with additional societal costs.
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Outcome measures, power analysis
and measurements
The primary outcome measure in this study was the number of
days that participants functioned within the normal range. In
order to function within the normal range they had to fulfil three
criteria: the level of social functioning had to be in the 95% range
of the normal population (assessed by the Social Functioning
Scale (SFS));19 there had to be no or minimal suffering from
residual symptoms; and there had to be no or minimal affect on
daily living of residual symptoms on the PSYRATS.
The secondary outcome measures included symptoms based
on the PSYRATS and the PANSS and quality of life assessed with
the scale of the World Health Organization (WHO–QoL).20
A power analysis was conducted. In order to show medium
effect sizes (0.50) with an alpha of 0.05 and a power of 0.80, at
least 70 participants were required in each condition at the end
of the study. As a conservative estimate, we anticipated about a
30% drop-out rate during 18 months and 230 participants were
planned to enrol.
All participants had assessments at months 0, 3, 6, 9, 12, 15
and 18. The number of days of normal functioning was estimated
at 91 if two consecutive measurements were within the range of
normal functioning. The number of days that a participant
functioned within the normal range was estimated at 45.5 if the
individual moved from below normal functioning to normal
functioning or the other way around. The number of days of
normal functioning was estimated at zero if the measurements
before and after both indicated below normal functioning. The
research assistants were trained and had a consensus meeting
every 3 months. They were masked to the treatment arm of
participants.
Treatments
A CBT therapist (psychologist) and a CBT assistant (nurse)
delivered CBT in the experimental condition. The first four
sessions were carried out by the CBT assistant and consisted of
a pre-therapy training of the concepts ‘antecedents’, ‘thoughts’,
‘feelings’ and ‘behavioural responses’. The goal was to teach
participants that people can have different thoughts about an
identical incident and consequently experience different emotions
and act differently.
The CBT therapist made an individual case formulation and a
list of goals with the participant and disputed alternative inter-
pretations of incidents and designed behavioural experiments to
test hypotheses. The CBT assistant could help with several
therapeutic procedures such as exposure to ‘dangerous’ places,
improving activity levels, exercises to improve self-esteem and
challenging ongoing dysfunctional thoughts.
The therapy was manualised in six steps: pre-therapy training
in the concepts: antecedent, thought, feeling and behaviour;
consumer information and mutual roles and demands;
assessment; shared case formulation and goal setting; changing
dysfunctional cognitions into more functional thoughts; and
consolidation. Therapy was provided in weekly sessions for 26
weeks but could end earlier when the participant attained the
goals set. The therapists met every 6 weeks for supervision and
mutual consultation. All sessions with the participants were
recorded on audiotape and a random selection of the tapes was
scored on treatment validity using the cognitive therapy scale.21,22
The TAU condition was routine care within each site and
typically consisted of pharmacotherapy and contacts with a
community psychiatric nurse. Some participants followed
educational programmes in managing medication, persistent
symptoms, addiction and work.
Costs and unit prices
The economic evaluation was conducted from a societal
perspective; costs in and outside the healthcare sector were
assessed. Medical costs of participants included medication,
in-patient care, community care and general healthcare. Costs of
the CBT intervention were registered in detail such as training
and supervision of psychologists and nurses during the study,
the number of sessions per participant, the wages of therapists
and additional aspects, such as the costs of therapy office and
accommodation. Both antipsychotic medication and non-prescribed
medication were included in medication costs.
In addition, various types of costs outside the healthcare
sector were included in the analyses. Time costs (related to the
CBT intervention) were based on the number of attended training
and therapy sessions, combined with information on the net
income of participants (shadow prices were used for participants
who did not have paid work). Costs of informal care were based
on the monetary valuation of the time invested by relatives or
acquaintances in helping or assisting the participant (household
work, accompanying individuals to healthcare professionals,
discussing problems related to the psychiatric condition, etc).
Out-of-pocket costs were additional costs generated by the
participants, such as the costs of cancelling holidays or other
planned activities. The cost of productivity losses due to illness-
related absence from work were estimated by means of the friction
cost method.23 Compensation mechanisms were taken into
account when estimating these productivity costs.24 Furthermore,
the costs related to changes in the amount of voluntary (unpaid)
work conducted by participants were taken into account.
Information on healthcare consumption was collected by
means of a detailed questionnaire that was filled in during an
interview covering the previous 3 months. If there was uncertainty
the research assistants checked the data using case histories.
Information on the use of antipsychotics was collected through
the healthcare professionals concerned. In order to facilitate
comparisons with other economic evaluations, unit prices (i.e.
the price of one unit of each included cost type) were mainly
based on Dutch standard prices for the year 2007.25 True costs
of used resources were estimated when standard prices were not
available.
Design of the economic evaluation
The economic evaluation was designed as a cost-effectiveness
analysis. In this type of analysis, costs and the primary health
outcome associated with an intervention are used to calculate
the incremental cost-effectiveness ratio (ICER) relative to one or
more alternatives.26 The formula used for calculating the ICER is:
ICER ¼ ðCCBT  CTAUÞðDNFCBT  DNFTAUÞ
where CCBT is mean costs in the CBT group; CTAU is mean costs in
the TAU group; DNFCBT is the mean days of normal functioning
in the CBT group; and DNFTAU is the mean days of normal
functioning in the TAU group.
Both costs and health outcomes were discounted in
accordance with current guidelines. The bootstrap method was
applied to provide information on the uncertainty of the results
of the economic evaluation.27 The ICERs were calculated for each
of the 2000 bootstrap iterations; simulated values of the mean
estimates for the cost and outcome differences were added to the
cost-effectiveness plane.28 Finally, cost-effectiveness acceptability
curves29 were calculated. Cost-effectiveness acceptability curves
inform decision makers on the probability that an intervention
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Cost-effectiveness of CBT for psychosis
will be cost-effective, which depends on the willingness to pay per
additional unit of health outcome.
Statistical procedures
Kolmogorov–Smirnov tests were done to check the normal
distribution of variables. To examine successful randomisation
and compare those who dropped out of the study with
completers, logistic regression and independent t-tests were used.
The EM algorithm with a bootstrap approach30 was applied to
deal with participants for whom not all the data were available
at the various time points. The analyses were conducted using
SPSS version 14 and R version 2.10.1 on Windows (R Foundation,
Vienna, Austria; http://www.r-project.org).31
Results
Baseline characteristics and participant flow
The participant flow can be seen in Fig. 1. Participants were
recruited between 1 April 2005 and 30 September 2006. Participants
were treated for 6 months and followed-up with assessments at
3-month intervals for 18 months. The 12 participants who
stopped therapy prematurely did so after one or two sessions.
The eight clerical errors are participants that ought to have been
referred to one of the therapists by the coordinating therapist
concerned, but who failed to do so. Nine individuals, who with-
drew consent, did so after they heard that they were randomised
to the TAU condition. The median number of sessions was 3 by
nurse therapists during pre-treatment training and 13 by
psychologists (intention-to-treat). Only 21 participants were
co-treated by a nurse therapist and psychologist; the median
number of session by the nurse therapist was 5.
The randomisation appeared to be successful. There were no
significant differences between the groups in the demographics
(Table 1). Logistic regression aimed at possible confounders found
no significant effects at baseline and end of treatment. A random
sample of four audiotaped sessions for each therapist were rated
for therapy fidelity: 97.8% of the recorded interviews were above
the fidelity score. The research assistants were asked to guess in
which condition the participants were at each assessment and
apparently grew more and more unmasked: 70% of the guesses
were actually correct.
Health outcome
The primary outcome measure in this study was the number of
days that participants functioned within the normal range. The
CBT group was functioning significantly better than the TAU
group at most of the time points when assessments were made,
except for the 9- and the 18-month assessment. A breakdown of
the composite dichotomous normal functioning outcome
measure showed that the gain in social functioning (SFS) was
comparable in both groups, but the CBT group experienced less
suffering and impact of symptoms (PSYRATS) on daily living than
the TAU group did. The number needed to treat varied from 5 to
10 on the intention-to-treat analysis (Table 2).
In the CBT group, the participants had on average 183 days of
normal functioning and the TAU group 106 days. The mean
difference of 77 days of normal functioning between groups was
significant (95% CI 29.7–124.0). The results of the secondary
outcome measures are shown in Table 3. The differences between
groups on the PANSS and the WHO–QoL were not statistically
significant. The subjective rating of symptoms on the PSYRATS
was statistically significant.
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Referred as possibly elegible n = 428
Enrolment n =216
Allocated to CBT (n = 110)
Withdrew consent: no economic data (n = 1)
Received allocated intervention (n = 89)
Did not receive allocated CBT (n = 20)
Stopped therapy prematurely (n = 12)
Clerical error (n = 8)
Followed up at:
Month 6: end of therapy (n = 94)
Month 12 (n = 89)
Month 18 (n = 99)
Analysed intention-to-treat (n = 109)
n = 6 Primary addiction
n= 34 No competence of Dutch language
n= 38 CBT in past year
n= 14 IQ 580
n= 120 Refused to participate
n= 10 Refused baseline assessment
Allocated to TAU (n= 106)
Withdrew consent: no economic data (n = 9)
Received allocated intervention (n = 97)
Followed up at:
Month 6 (n = 71)
Month 12 (n = 75)
Month 18 (n = 87)









Fig. 1 The flow of the participants in the study. CBT, cognitive–behavioural therapy; TAU, treatment as usual.
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Costs and healthcare utilisation
The various medical and non-medical costs generated by both
groups are presented in online Table DS1. The mean total costs
of training therapists in CBT, supervising therapists during the
study, and providing pre-therapy to participants was e426. The
costs of the CBT sessions during the first 6 months of the study
were included in the costs of contacts with psychologists, which
were therefore higher in the CBT condition (approximately e550
of these costs were related to CBT sessions). Although the
percentage of participants who were admitted during the study
was comparable between groups, a small number of participants
in the CBT group was admitted during most of the study period,
leading to considerably higher costs. An overview of the total costs
incurred over the duration of the study, broken down by time
period, is provided in Table 4. The differences between the mean
costs of both groups were not statistically significant. This should
be interpreted with some caution, since the study was powered (as
most economic evaluations) to demonstrate differences in health
outcomes and not costs.
Cost-effectiveness analysis
The calculated value of the ICER was e47 per day with normal
functioning gained. The point estimate of the ICER and the results
of the bootstrap analyses are presented in the cost-effectiveness
plane in Fig. 2.
About 21% of the bootstrapped mean ICERs were located in
the southeast quadrant, indicating that CBT dominated TAU in
21% of the bootstrapped mean ICERs. The other bootstrap
simulations (79%) were located in the northeast quadrant
indicating that both costs were higher and health outcomes were
better in the CBT group. Interpretation of outcomes in the
northeast (and southwest) quadrant depends on how much
decision makers are willing to pay for an additional unit of health
outcome. In Fig. 3, the graph for the standard analysis shows the
probability that CBT (compared with TAU) will be cost-effective
for increasing willingness to pay per additional unit of health
outcome. For instance, a willingness to pay approximately e84
per additional day of normal functioning is associated with a
70% probability that CBT is the optimal intervention.
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Table 1 Demographic characteristics of cognitive–behavioural therapy (CBT) and treatment as usual (TAU) groups
Characteristic CBT group (n=109) TAU group (n=97)
Age, years: mean (s.d.) 36.52 (11.18) 37.45 (10.61)
Duration of illness, years: mean (s.d.) 10.14 (7.59) 11.02 (8.37)
Male, % 69 73
Education,b mean (s.d.) 4.20 (1.80) 4.32 (1.93)
Social Functioning Scale, total score: mean (s.d.) 112.17 (21.27) 109.59 (21.85)
Positive and Negative Syndrome Scale, total score: mean (s.d.) 67.71 (13.21) 70.21 (12.81)
Participants with delusions, % 81 86
Participants with hallucinations, % 61 65
a. All t-tests and w2 were not significant.
b. Range from Level 1, special school to Level 7, university.
Table 2 Number of participants with normal functioning at different time points for the cognitive–behavioural therapy (CBT) and
treatment as usual (TAU) groups: intention-to-treat
Normal functioning at assessment CBT (n=109) TAU (n=97) Fisher’s exact test
Number needed to treat
(95% CI)
3 months 34 10 0.000 5 (3.2–9.7)
6 months 31 14 0.018 8 (4.0–33.1)
9 months 33 20 0.150 10 (ns)
12 months 40 20 0.014 7 (3.5–25.2)
15 months 42 24 0.037 8 (3.8–79.9)
18 months 39 25 0.134 10 (ns)
ns, not significant
Table 3 Differential effects of cognitive–behavioural therapy (CBT) and treatment as usual (TAU) on symptoms and quality of life
over the study period
CBT, mean (s.e.) TAU, mean (s.e.)
Interaction group6
Baseline End of treatment Baseline End of treatment F time point Pa
Positive and Negative Syndrome Scale, total 67.9 (1.3) 61.2 (1.5) 70.7 (1.3) 62.7 (1.6) 0.51 0.48
Psychotic Symptoms Rating Scale, total 29.9 (1.3) 19.9 (1.6) 32.8 (1.4) 27.8 (1.8) 4.40 0.04
World Health Organization – Quality of Life, total 71.9 (1.0) 75.1 (1.0) 73.5 (1.0) 75.4 (1.3) 0.76 0.39
World Health Organization – Quality of Life,
psychological well-being 17.7 (0.3) 18.4 (0.3) 18.1 (0.3) 17.9 (0.4) 3.70 0.06
a. F-statistic testing quality of linear slope coefficients from a linear mixed model with an unstructured covariance structure. Information criteria used: –2 restricted likelihood ratio.
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Sensitivity analyses
In the first sensitivity analysis, participants in one of the six
participating centres were left out of the analyses (n=11; 5%).
Outcomes of individuals in this centre were very distinct from
the other centres: with considerably more hospitalisations and less
experienced therapists. Excluding these participants led to lower
average costs in the CBT group (e30 652) and the TAU group
(e28 789), and a smaller mean difference of e1863 (CI –6918 to
10 647) between CBT and TAU.
In the second sensitivity analysis, we adjusted the way the
number of days of normal functioning was calculated. A more
liberal threshold for normal functioning was chosen, allowing
one 2-score (moderate severe) on either suffering or the impact
of symptoms. The mean difference in days of normal functioning
between groups was now 58 days in favour of CBT.
In the third sensitivity analysis, participants who had been
admitted to a hospital during the 3 months before the start of
the study were excluded from the analysis. Results showed that
mean total costs in both groups were much lower (CBT group
(n= 81) e24 885, TAU group (n=73) e23 585), and the difference
between the groups (e1300, CI –7450 to 9949) was much smaller
than in the previous analyses. For this analysis, the incremental
costs were e14 per additional day of normal functioning gained.
Fig. 3 presents the cost-effectiveness acceptability curves assessed
for each of the described sensitivity analyses.
Discussion
Normal functioning and costs
This study shows that implementing CBT in routine care can
alleviate the suffering of people with persistent psychosis and
brings some of them into the range of normal functioning, with
low levels of distress and minimal impact of the symptoms on
their daily life. However, the additional health gains for
participants in the CBT condition were accompanied by higher
costs. Decisions on the further implementation of CBT are
dependent on what decision makers are willing to pay for the
incremental health gains. In this study, CBT was more likely to
be cost-effective than TAU when the willingness to pay for an
additional day of normal functioning gained would be higher than
e47.
The overall mean total cost estimates per participant appeared
to be in line with a recent economic study aimed at first-episode
psychosis,3 and were generally higher than other cost results
published in the last decade.10–14 This may at least be partially
because of the widening scope of costs included in economic
studies, differences in costing methods applied, and increased
use of more expensive antipsychotics in recent years. Furthermore,
this study confirmed the widely acknowledged influence of
hospital admissions3,32 on the total costs in patient populations
with psychosis.
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Table 4 Mean total costs (Euro, price level of 2007) during the study
Cognitive–behavioural therapy Treatment as usual
Time period n Total costs, mean n Total costs, mean Difference in costs, mean (95% CI)a
0–3 months 97 7158 77 5084 2074 (729 to 4275)
3–6 months 94 5824 69 4888 936 (7931 to 2902)
6–9 months 88 5141 75 4840 300 (71805 to 2282)
9–12 months 89 5222 75 3873 1350 (7314 to 2968)
12–15 months 96 4617 85 4963 7346 (72272 to 1521)
15–18 months 99 4301 87 3777 524 (7873 to 1969)
0–18 monthsb 109 33 130 97 29 578 3552 (75162 to 12 184)
a. 95% CI for the mean cost differences between the various groups during the time periods studied.
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Fig. 2 Results of the cost-effectiveness analysis and bootstrap
method.
CCBT, mean costs in the cognitive–behavioural therapy (CBT) group; CTAU, mean costs
in the treatment as usual (TAU) group; DNFCBT, mean days of normal functioning in
the CBT group; DNFTAU, mean days of normal functioning in the TAU group. The
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With adjusted threshold for normal
functioning
With exclusion of participants hospitalised
in the 3 months prior to study
Standard analysis
Fig. 3 Cost-effectiveness acceptability curves based on the
standard analysis and the additionally conducted sensitivity
analyses. CBT, cognitive–behavioural therapy.
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Hospital admissions and CBT
Although the experimental group was more likely to experience
normal functioning, they also had double the in-patient costs.
We have looked into the distribution of the days spent in hospital.
These are skewed and the CBT group had 21 participants and
the TAU group 15 participants with more than 60 in-patient days.
The top seven outliers in the CBT group consumed 60% of
all in-patient days. Five of these people were already long-stay
in-patients when they were included in the study. It seems to us
that CBT did neither cause admission nor lengthened the hospital
stay. Six of the participants had almost no exposure to CBT and
stopped after an average of 2.5 sessions with zero days of normal
functioning. The one person that did have 19 sessions of CBT also
improved to normal functioning for a period of 182 days.
Strengths
Important strengths of this study are the naturalistic study design
and the relatively large number of participants. The study can be
generalised to people with schizophrenia-spectrum disorders with
persistent psychosis, because the number of exclusions is quite
small. Medication was not kept fixed during the trial. Many
medication regimes were switched during the study or dosages
were calibrated to optimum levels. Only 54 people (12.6%) were
excluded because of primary addiction, low IQ or no competence
in the Dutch language; and 38 potential participants (8.8%)
because they had undergone CBT in the past. A total of 120 people
(28%) refused to take part in the study, which is comparable with
previous findings in such studies. Of the 110 individuals who were
randomised to the CBT group, only 12 individuals (11.0%)
stopped treatment prematurely, which indicates that the inter-
vention was very well tolerated. Furthermore, the participating
therapists all worked in routine care services all over the country.
All participants fulfilled broad inclusion criteria. Contrary to
efficacy trials, individuals with disorganised and undifferentiated
symptoms were not excluded, although communication, memory,
learning potential and acting on plans are all compromised in
these participants. Individuals in these subgroups had higher
symptom scores than the paranoid and schizoaffective subgroups,
and although they improved over time, they were still more
symptomatic. In this real-life environment the CBT group
attained normal functioning more often than the TAU group.
Another strength of the study is the long follow-up period.
Importantly, the effects of CBT may wane over time, while the
costs are stable after the intervention period. If individuals benefit
from CBT after 18 months, making no additional therapy costs,
the costs per day of normal functioning would reduce further.
Long follow-up periods are more realistic in a relapsing condition
such as schizophrenia. There will always be more moderate results
on the outcome measures, but the mean accumulating costs will
reduce after therapy termination.
Limitations
This study also had several limitations from both a clinical and
economic point of view. First, CBT in psychosis is a complex
intervention that requires expertise in psychopathology and
treatment techniques. Some of the therapists were novices and
trained and supervised during the study, but for optimum
performance several years of experience are required.33 This might
explain site differences that resulted from different admission
policies and differences in the expertise of the therapists. Also
the commitment to supervision varied between centres.
Second, the primary outcome measure applied in this study is
of concern. In the field of health technology assessment, there have
been debates on the topic of adequate outcome measures for
economic evaluations. Currently, most guidelines recommend
the use of quality-adjusted life-years (QALYs). The primary
outcome measure used in this study, days of normal functioning,
does also seem to be relevant for policy decisions. However, the
outcome cannot directly be compared with QALY analysis used
in other studies. Moreover, there is no consensus on acceptable
(cost) benchmarks per additional day of normal functioning
gained. For the moment, policy makers will have to decide
whether the presented willingness to pay values, and the associated
probability outcomes, justify the (further) implementation of CBT
in the healthcare system.
The final limitation concerns the generalisability of current
findings to other healthcare systems. Directly transferring current
results may be troublesome, not only because of substantial
differences in healthcare systems but also to (international)
variations in the costing methods applied.
When we consider the findings of this study, we must state
that effects on symptoms as measured with the PANSS were
absent, but that CBT did succeed in reducing the suffering from
persistent psychotic symptoms and their impact on daily life
and improved social functioning. Cognitive–behavioural therapy
is not a quasi-antipsychotic. Psychotic symptoms can persevere,
but the individual’s appraisal of psychosis can be changed with
CBT. Reductions in mood symptoms more than reductions in
psychotic symptoms probably facilitate emotional well-being
and social functioning in these individuals. This was also found
in a recent trial to prevent relapse with CBT.34
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Cost types Costs, mean (s.d.) %a Costs, mean (s.d.) %a
Intervention
CBT (training/supervision therapists, training participants) 426 (112) 94 – 0
In-patient and semi-in-patient care
Hospital admission 11 900 (28 663) 33 6379 (14 606) 35
Day care 1030 (3274) 16 1339 (4030) 18
Sheltered accommodation 5464 (13 833) 18 4897 (13 337) 15
Out-patient and community care
Psychiatrist 339 (370) 91 363 (479) 86
Psychologist 613 (488) 84 89 (259) 35
Group therapy 67 (222) 31 85 (210) 27
Social-psychiatric nurse 431 (502) 80 514 (507) 79
Social worker 55 (300) 18 44 (222) 16
Crisis intervention 45 (128) 15 47 (136) 14
Psychiatric home care 334 (815) 28 284 (621) 27
Consultation office for alcohol and drug addiction 30 (202) 3 46 (309) 5
Other out-patient care 475 (847) 60 619 (1 229) 66
General healthcare
General practitioner 23 (94) 30 17 (40) 31
Alternative healthcare 2 (11) 3 38 (297) 7
Home care 492 (1161) 28 443 (1457) 26
Emergency care 15 (80) 6 73 (687) 3
Other general healthcare 6 (33) 9 9 (44) 12
Day activity institutions
Day activity centre 190 (504) 33 186 (379) 39
Drop-in centre 180 (612) 22 185 (603) 29
Other institutions 93 (315) 22 56 (198) 14
Medication
Antipsychotics 1462 (1770) 95 1738 (1686) 96
Non-prescribed medication 78 (492) 17 37 (278) 11
Non-medical costs
Time costs 124 (53) 96 – 0
Informal care
Household work 328 (1079) 30 286 (688) 27
Other 2732 (4380) 81 3250 (4410) 80
Out-of-pocket costs 108 (837) 13 202 (745) 16
Productivity losses
Unpaid work 121 (382) 21 175 (489) 26
Paid work 637 (2236) 17 587 (1957) 16
a. Percentage of participants using the cost types specified.
